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Abstract 
Although bone mineral density (BMD) measurement is the common method for the diagnosis of postmenopausal 
osteoporosis (PMO, bone turnover markers have been proposed as good indicators for monitoring the efficiency 
of antiresorptive treatment.  We aim to evaluate course of bone turnover markers in the follow-up of treatment 
osteoporosis and compare the results of these markers with bone mineral densities. 47 postmenopausal patients 
were included in this study. The age average of the patients was 59.17.6 (48-81). Patients were divided into 5 
groups depending on the type of the treatment: Calcium and vitamin D (8 patients); calcium, vitamin D and 
risendronate (10 patients); calcium, vitamin D and alendronate (10 patients); calcium, vitamin D and hormone 
replacement therapy (tibolone) (9 patients) and calcium, vitamin D and calcitonine (10 patients). Samples were 
taken from each group, prior to treatment and in the third and sixth months of the treatment. Bone mineral 
density measurements were carried out before the treatment and in the sixth month. The basal concentrations of 
bone turnover markers serum Type I collagen C-telopeptide (CTX), N-mid-Osteocalcin (OC) and urinary 
deoxypridinoline (Dpd) and Interleukin-1 (IL-1) were compared to the values in the third and sixth month of 
the therapy and also to BMD.OC, CTX and Dpd are good markers for the evaluation the effectiveness 
antiresorptive therapy. The changes  in CTX and OC seems to be reflect the changes in bone mass in the early 
period. However, the changes in Dpd levels come out later.  HRT (tibolone) and biphosphonates especially 
risendronate are thought to be effective therapeutic approaches, because a significant decrease in bone turnover 
markers and an improvement in BMD – especially in lombar vertebra - were observed in the follow up of 
treatment. A good correlation found between the changes in levels of CTX and Dpd and changes in BMD during 
treatment, which suggest that these two markers would be useful for monitoring response to antiresorptive 
therapy. 
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1. Introduction 
PMO is a disease characterised by low bone mineral  denisty and microarchitecural  impairment -as result of 
reduction in circulating estrogen causing an accelerated bone turnover and resorption- which lead to bone 
fragility and an increase risk of fractures. It is a very serious health problem leading to significant morbidity, 
disability, mortality and decreased quality of life (1,2). Bone mineral density  (BMD) measurement is the most 
common method used for the diagnosis and the follow-up of the treament of osteoporosis (3). However, changes 
in BMD measured by densitometry are not detected until the bone loss is great, therefore it would be useful to 
have dynamic tests that could reflect the changes earlier (4). In recent years, for the evaluation of efficiency of 
the treatment of osteoporosis, bone formation and resorption markers are being used. With these markers, earlier 
information can be obtained when compared to bone mineral density measurement, so that they may be used to 
detect patients who do not respond to therapy (5,6). The magnitude and the timing of reduction (within weeks) in 
the levels of bone turnover markers are thought to be  their advantage when compared to BMD measurements  
by which slower changes and smaller magnitude are obtained (7).  
Antiresorptive agents (biphoshonates and calcitonin), hormone replacement therapy (ERT-tibolone) and 
calcitriol (1,25 dihydroxyvitamin D) with calcium supplementation are the most widely used treatments in PMO. 
Biphosphonates directly reduce the bone turnover by inbiting the activity of osteoclasts (3,8) . Randomized 
placebo-controlled studies with alendronate and risendronate show their effect on inducing the gain of BMD,  
reducing the increased rates of bone turnover and decreasing the risk of fractures (2,9,10). In previous studies, it 
was shown that calcitriol increases bone mass not only at lumbar spine but also at femoral neck (11,12). Another 
common therapeutic approach, calcitonin stimulates the increase in bone mass and also decreases in bone 
resorption markers and OC levels (13,14). Tibolone, synthetic estrogenic, prosgestagenic and androgenic steroid, 
reduces bone resorption by decelerating bone turnover (15). Recent studies have revealed that tibolone is 
effective in incerasing the bone mass and that was proved  by the increase in BMD measurement and decrease in 
bone turnover markers (16,17). 
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In this study, we aim to show that the bone turnover markers are as reliable as BMD measurement in the 
follow-up of the treatment of PMO and  reflect the changes in bone mass earlier and  also, to select the earliest 
marker that can reflect the changes in BMD. 
 
2. Patients and Methods 
2.1.Subjects  
Forty-seven  postmenopausal women aged 48-81 (59.17.6) who were admitted to Fatih University Faculty of 
Medicine Department of Obstetrics and Gynecology were taken in this study. Osteoporosis was confirmed with 
BMD measurement. 
The patients were in menopause for 5 years and  diagnosis of osteoporosis was made according to the 
criteria declared by  World Health Organisation. None of the patients had used medication neither for 
osteoporosis nor effecting bone mass and none had a disease that effects bone metabolism or  cause secondary 
osteoporosis. 
All patients were given Ca 1500 mg, D vitamini 400 IÜ daily. They  were divided into 5 groups depending 
on the type of the treatment: only calcium and vitamin D (8 patients); calcium, vitamin D and risendronate (10 
patients); calcium, vitamin D and alendronate (10 patients); calcium, vitamin D and hormone replacement 
therapy (tibolon) (9 patients) and calcium, vitamin D and calcitonine (10 patients). Blood and urine samples 
were taken from each group, prior to treatment and in the third and sixth months of the treatment. Bone mineral 
density measurements were carried out before the treatment and in the sixth month. 
 
2.2 Assays  
The blood and urine specimens were immediately santrifuged, seperated and stored at -20oC till analysis. Serum 
calcium (Ca), phosphorus (P), creatinine (Crea),  alkaline phosphatase (ALP) levels and urinary calcium and 
creatinine levels were measured by Hitachi 912 (Roche Diagnostics Co., Mannheim, Germany) autoanalyzer. 
The creatinine clearance is calculated according to the formula. Serum IL-1 and urinary DPD (Pyrilinks-D) 
levels were measured by IMMULITE One  Analyzer (DPC Diagnostic Products Co., CA, USA) using 
chemiluminescent  immunoassay. Serum CTX (-crossLabs) ve N-mid OC levels were measured by Roche 
Elecsys 2010 Analyzer (Roche Diagnostics Co., Mannheim,Germany) using electrochemiluminescent 
immunossay. All the analysis were made in single run after and calibration of the assay was controlled by 
spesific control seras. The inter-assay and intra-assay coefficients of variation (%CV) are shown in the Table 1.  
Table 1. The inter-assay and intra-assay %CV for the parameters 
Tests İntra assay İnter assay 
Mean % CV Mean %CV 
Serum Ca (mg/dl 8.48 0.9 8.38 1.5 
Serum Crea (mg/dl) 1.54 0.9 1.54 2.1 
Serum P (mg/dl) 1.38 0.9 1.91 1.4 
Serum ALP (U/L) 458 0.5 357 2.2 
Urinary Crea (mg/24 h) 23.97 0.8 24.44 2.1 
Urinary Ca (mg/24h) 14.28 0.8 13.96 1.2 
Serum CTX (ng/ml) 0.08 4.6 0.08 4.7 
Serum OC (ng/ml) 6.95 0.7 7.04 1.6 
Serum  IL-1 (pg/ml) 39 2.8 13 7.7 
Urinary DPD (nM DPD/mM crea) 30 15 30 20 
 
2.3.Bone Mineral Density 
BMD of lumbar vertebra (L2-L4), femur neck and Ward’s triangle were measured by dual energy X-ray 
absorptiometry (Lunar Radiation Corporation)  at the beginning and in the sixth month of the treatment.  
 
2.4.Statistics  
The sattistical analysis  was performed with SPSS for Windows 9.0 software programme. One-way analysis of 
variance (ANOVA) and Banferroni test  were used to compare the changes between groups for normally 
distributed variables and Kruskall-Wallis analysis of variance for the non- normally distributed variables. To 
compare the changes due to time with in the groups, ANOVA for the normally distributed variables and Paired t 
ve Wilcoxon test were used. Pearson correlation analysis method was used for the correlation analysis. Results 
were given as mean  SD. Statistical significance was assumed with p<0.05. 
 
3. Results  
The groups were well matched in age, the age of menopause and menarche ??, BMI (Body Mass Index), 
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smoking and creatinine clearance (Table 2). During the follow-up no fractures or side effects  occured. 
Table 2. Demographic characteristics of the patients 










Age 58.32.9 60.88.3 61.17.6 55.58.0 59.59.2 
Age of menarche 13.11.1 13.91.1 13.11.9 13.31.0 12.91.1 
Age of menopause 45.14.8 48.23.1 46. 4.3 48.15.5 47.64.1 
BMI (kg/m2) 23.01.0 24.73.1 26.07.1 26.53.9 26.24.4 
Smoking 4 (%50) 2 (%20) 5 (%50) 2 (%22) 2 (%20) 
Lombar vertebra, femur neck, Ward’s triangle BMD  values of the groups were compared with eachother (Table 
3).  
 
Table 3. Baseline and sixth month BMD values 
 Lombar Vertebra Femur Neck Ward’s Triangle 







































































* Significant difference in sixth month compared to baseline (p < 0.05) 
The increase in lombar vertebra, femur neck ve  Ward’s triangle scores in the sixth month were 
significantly different for the group I and III when compared to baseline values (p<0.05). For the groups II, IV 
and V significant difference was seen only in lomber vertebra scores (p<0.05).   
During the siz month follow up, the changes in bone turnover parameters in time and in and between the groups 
are shown in Figure1 and Table 4. 
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Table 4. The changes in bone turnover parameters in time and in end between groups 
 OC 1 CTX 2 
Baseline 3rd month 6th month Baseline 3rd month 6th month 
Group I 32.64.3 32.66.2* b 27.25.16*c 0.450.22 0.630.12* 0.560.48c 
Group II 28.512.21a 19.89.2b 15.87.6c 0.370.372a 0.20.18 0.060.06c 
Group III 24.811.9 21.110.1 14.45.4c 0.260.19 0.200.17* 0.10.07c 
Group IV 21.05.8a 16.65.6 14.76.5c 0.290.19a 0.180.12 0.160.10c 
Group V  21.314.0 17.39.9 16.711.5 0.240.12 0.190.13 0.170.15 
 
 Dpd 1 IL-1 
Baseline 3rd month 6th month Baseline 3rd month 6th month 
Group I 24.13.2a 17.02.50* 20.414.3 5.070.1 4.960.11 4.900.9c 
Group II 30.612.9 23.210.9b 15.76.28c 5.230.2a 5.100.13b 4.901.13c 
Group III 35.318.8 33.115.2*b 21.310.5c 5.220.2 5.100.13b 4.950.11c 
Group IV 35.628.9a 19.411.9 15.76.35c 5.10.1a 5.040.15b 4.900.14 
Group V  34.620.1a 24.09.6b 20.036.8 5.020.8 5.010.09b 4.940.18 
 
 sCa sP 
Baseline 3rd month 6th month Baseline 3rd month 6th month 
Group I 10.360.24* 10.550.2*b 10.050.20 4.810.34* 4.250.53* 4.360.31* 
Group II 9.650.59* 9.80.43* 9.860.50 3.690.52 3.670.45 3.590.55* 
Group III 10.050.65 10.160.44 9.950.43 3.790.55 3.850.57 3.740.57 
Group IV 9.750.37 9.760.61* 9.970.73 3.540.67 3.250.43*b 3.680.40 
Group V 10.080.44 10.050.66 9.870.63 3.630.46 3.620.44 3.570.41* 
 
 ALP uCa 
Baseline 3rd month 6th month Baseline 3rd month 6th month 
Group I 205.610.1a 193.04.03b 17415.3c 96.7173.8a 119.919b 161.188c 
Group II 180.846.9 153.051.4a 139.147b 89.0136.4c 91.2433.7 90.7054.2 
Group III 198.555.1 182.041.4 171.052.1 84.167.0 64.8861.0 96.4569.0 
Group IV 158.526.8a 141.416.7 155.321.8 80.4755.1 84.5845.7 79.3850.4 
Group V 163.431.9 160.934.0 153.833.8 124.6100. 108.553.5 95.0666.6 
*  :  significantly different compared to other groups (p<0.05) 
a  : significant difference between baseline and 3rd month  
b  : significant difference between 3rd month and 6th month 
c  : significant difference between baseline and 6th month  
1  :  borderline difference due to time and treatment groups  
2  : significant difference due to time and treatment groups (p<0.01) 
Baseline OC levels were found similiar between the groups when we compare the five treatment groups. 
However, in group I the elevation in the 3rd and 6th month found different when compared to other groups 
(p<0.05). Dpd levels were found significantly lower in 3rd month in group I (p<0.05) and significantly higher in 
group III (p<0.05). For serum Ca levels, baseline values were significantly higher  in group I and lower values in 
group II and 3rd month values were found significantly higher in group I and lower in group II and IV (p<0.05). 
Serum baseline P levels were found only different in group I (p<0.05). In the 3rd month, the elevation in group I 
and the fall in group IV and in the sixth month the elevation in group I and fall in group II and V were found 
significant (p<0.05). CTX, IL-1, ALP and urinary Ca levels show no difference in groups.   
When we compare the parameters in group I due to time, OC levels  decrease in the 6th month when 
compared to baseline and 3rd month (p<0.01). Only significant decrease in CTX levels  was seen in between 3rd 
and 6th month (p<0.01). Dpd levels were found to decrease in 3rd month (p<0.01) and IL-1 levels were found 
significantly different between the baseline and sixth month (p<0.05). Significant decrease was seen in 6th 
month when compared to 3rd in serum ca levels (p<0.05). The decrease in all ALP and urinary Ca levels were 
significant (p<0.05), but no difference was observed in P levels. 
For the parameters in group II, OC levels in the 3rd month compared to baseline and in the sixth month 
compared to 3rd  were found significantly lower (p<0.01,p<0.05). CTX levels were lower in 3rd and 6th month 
compared to baseline (p<0.05). Dpd levels in the 6th month were lower than the baseline and the 3rd 
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month(p<0.05). The decrease in IL-  and ALP levels were found significant although  they were in normal 
range (p<0.05). No significant difference were noted for urinary Ca and serum P levels. 
OC and CTX were foun lower  only in the 6th month compared to baseline(p<0.05) in the group III.  The 
difference in Dpd  and IL-1 levels were detected in the 6th month when compared to baseline and  3rd 
month(p<0.01, p<0.05). No significant difference were noted for serum and urinary Ca, serum P  and ALP levels. 
We found significant decrease in OC, CTX and Dpd levels in the 3rd and 6th month in group IV when 
compared to baseline (p<0.05), however the difference between the 3rd and the 6th month was insignificant. The 
significant decrease were seen between the 3rd and the 6th month for IL-1 levels (p<0.01), in the 3rd month for 
ALP levels (p<0.05) and in the 6th month for P levels (p<0.05). 
In group V, Dpd levels were significantly lower in 3rd month than baseline and in 6th month than 3rd 
month (p<0.05) and IL-1  levels decrese in the 6th month compared to 3rd month (p<0.05). 
When we evaluate the results depending on the comparison either between the groups or due to time, we 
found that the difference for OC (p= 0.68)  and Dpd (p=0.71) were at/in? borderline, for CTX it is significant  
(p<0.01), and for IL-1, serum Ca, ALP, P ve urinary Ca it is insignificant. 
BMD scores seems to correlate with OC, IL-1, Dpd and P levels at the beginning of the treatment and with 
OC, CTX and Ddp levels in the 6th month. A correlation was observed between OC and CTX levels not only at 
the beginning but also in the 6th month. 
 
4. Discussion  
Osteoporosis is a common health problem for the postmenopausal women.  In recent years, researchers aim to 
find new bone spesific parameters that will facilitate the early diagnosis and the follow-up of osteoporosis.  
Osteoporosis  is diagnosed by BMD measurement. It was shown that increased bone turnover is correlated 
with bone loss. Bone loss can be evaluated by bone turnover markers because, the bone mass is determined by 
bone turnover (18,19). These markers are used to give information about the BMD in an early period than BMD 
measurement (20,21) 
Osteoclastic bone markers Tartarate resistant acid fosphatase (TRAP), Hyroxyproline (Hyp), Pridinoline 
(Pyd), Deoxypiridinoline (Dpd), Type I collagen N-telopeptide (NTX), Type I collagen C-telopeptide (CTX) 
reflect the bone resorption and formation markers derived from osteoblasts Osteocalcin (OC), alkaline 
phosphatase (ALP), type I collagen propeptides) inform us about the future bone loss (20,22,23). In 60-70%  of 
women with early postmenopausal osteoporosis , TRAP,OC, urinary Ca, Hyp and Dpd show bone loss (18,19). 
Chaki et al. noted that bone spesific ALP, CTX, NTX, OC, Pyd, Dpd can be used to predict future BMD in 
postmenopausal women (24). 
Calcitonin is commonly used in the osteoporosis treatment (25,26).  In short-term and long-term placebo 
controlled studies calcitonin was denoted to be an effective treatment (26,27). 
In two previous studies, treatment with tibolone increased BMD and decreased OC and CTX levels and this 
deceleration in markers are found to be inversely proportional to BMD (28,29). It was also revealed that serum 
CTX  levels  reflect the bone loss and future fracture risk (30). Rymer et al. showed that tibolone increased 
vertebra and femoral neck BMD and cause a decrease in OC and ALP levels in three different long term studies 
(26,32,32). Also, some other studies support these results and verify the efficiency of tibolone on BMD (17,33-
35). Parviainen et al., Christagau et al.  and Bjarnason  et al noted that tibolone significantly decreases Dpd, CTX  
and OC levels (36-38). 
In their placebo controlled long-term study Greenspan et al. concluded that CTX and NTX predict long-
term changes in vertebral BMD in women receiving alendronate (39).  Combined treatment with biphosphonates 
and HRT had a favorable effect on BMD and also decrease bone spesific ALP, NTX, CTX, Dpd levels (40-42). 
Also, OC levels well correlate with the improvement  in  BMD  made by combined treatment with calcitonin and 
HRT and can be used in the follow-up of treatment (13,14,43,44). And also by calcitonin therapy while the BMD 
increases, CTX levels decreases (45). However, there are adverse results of studies about calcitonin in which no 
change in OC levels were observed (46,47). 
In this study, a bone formation marker – OC, two resorption markers – CTX and Dpd-  and a cytokine -IL-
1- which  thought to have effect on bone turnover were analysed and the suitable marker/markers that can 
reflect future KMD and that can be used to evaluate the efficiency of treatment are aim to be investigated.  
Just about all the parameters analysed start to decrease in the first three months. However, in risendronate and 
tibolone groups the decrease were significant. The decrease in OC, CTX and Dpd levels in the 6th month 
correlate with the KMD scores. 
It is known that the antiresorptive treatment given inhibits bone resorption and indirectly effects on bone 
formation. In our study,  CTX and OC decreases in four groups except the calcitonin group. Also, in tibolone and 
risendronate group the decreased revealed earlier (in the 3rd month). OC and CTX levels were in correlation 
during the six months period. The decrease in Dpd levels found insignificant only in the group which was given 
Journal of Health, Medicine and Nursing                                                                                                                                          www.iiste.org 




only Ca and vitamin D. Other groups had shown signifiant decrease in the 6th month, also, this descending 
began in the 3rd month in tibolone group. No statistical difference was found between CTX and OC levels in 
evaluating the effectiveness of treatment or reflecting the future bone status. 
Estrogen defficiency has the major role in postmenopausal osteoporosis. Recent studies direct us to a fact 
that, estrogen stimulates the secretion of local factors that effect bone remodeling and in the absence of estrogen 
this mechanism is impaired (48). IL-1 is one of these factors that stimulates the differentiation and activation of 
osteoclasts. IL-1 is inreased in some cases with estrogen deficiency except menopause and this supports the 
modulator effect of estrogen on cytokines (49-52). IL-1 levels were significantly higher in women with 
potmenopausal osteoporosis compared to healthy ones and also found inversely proportional to the BMD (53,54). 
Also, studies with different results exist. In these studies no difference was observed in IL-1 levels in 
postmenopausal period and no correlation was detected with BMD (55,56). 
In our study, the IL-1 levels were decreased in risendronate in the 3rd month, but significant difference 
was detected in other groups in the 6th month. No correlation between IL-1 levels and BMD were observed. 
This prevensts IL-1 to be the marker. 
Only the change in CTX levels between groups and due to time is significant. The significance for OC and 
Dpd is in/at?? borderline. The changes in IL-1, serum Ca, ALP, P and urinary Ca levels  are insignificant. 
Lombar vertebra BMD scores were significantly elevated in all treatment groups. The increase in femur 
neck and Ward’s triangle scores are increased in Ca and vitamin D group and in risendronate group. The 
correlation between the BMD and OC and CTX were significant in the 6th month.  
We concluded that, CTX and OC are the suitable markers for the follow-up of the treatment of 
postmenopausal osteoporosis. The changes in their levels also give information about the future-period bone 
mineral density. Considering the decrease in these parameters and the increase in the bone mineral density, the 
most appropriate treatments were determined as tibolone and risendronate and with these treatments, 
improvement in bone mineral density became most evident in lomber vertebra. 
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